Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX.
van der Sijde F, Azmani Z, Besselink MG, Bonsing BA, de Groot JWB, Groot Koerkamp B, Haberkorn BCM, Homs MYV, van IJcken WFJ, Janssen QP, Lolkema MP, Luelmo SAC, Mekenkamp LJM, Mustafa DAM, van Schaik RHN, Wilmink JW, Vietsch EE, van Eijck CHJ.
van der Sijde F, et al. Among authors: vietsch ee.
Ther Adv Med Oncol. 2021 Aug 18;13:17588359211033704. doi: 10.1177/17588359211033704. eCollection 2021.
Ther Adv Med Oncol. 2021.
PMID: 34422118
Free PMC article.